Your browser doesn't support javascript.
loading
123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy.
Laursen, Adam H; Thune, Jens Jakob; Hutchings, Martin; Hasbak, Philip; Kjaer, Andreas; Elming, Marie B; Ripa, Rasmus S.
Afiliación
  • Laursen AH; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • Thune JJ; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Hutchings M; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
  • Hasbak P; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
  • Kjaer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
  • Elming MB; Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Ripa RS; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
Clin Physiol Funct Imaging ; 38(2): 176-185, 2018 Mar.
Article en En | MEDLINE | ID: mdl-28251781
Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. 123 I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of 123 I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of 123 I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cintigrafía / Fibras Adrenérgicas / Antraciclinas / Radiofármacos / 3-Yodobencilguanidina / Corazón / Radioisótopos de Yodo / Antibióticos Antineoplásicos / Cardiomiopatías Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Clin Physiol Funct Imaging Asunto de la revista: FISIOLOGIA / PATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cintigrafía / Fibras Adrenérgicas / Antraciclinas / Radiofármacos / 3-Yodobencilguanidina / Corazón / Radioisótopos de Yodo / Antibióticos Antineoplásicos / Cardiomiopatías Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Animals / Humans Idioma: En Revista: Clin Physiol Funct Imaging Asunto de la revista: FISIOLOGIA / PATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido